Skip to main content

Table 4 Patient characteristics and incidence of comorbidities of HAM-net-registered patients

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

HAM-net-registered patients observed for at least one year (n = 434)
Sex: Female 327 (75.3%)
Age at baseline (year)a 61.9 ± 10.6
Age at onset (year)a 44.4 ± 14.8
Disease durationa (time from onset to the baseline) 16.3 ± 11.1
Baseline OMDSa 5.7 ± 2.2
Rapid progressorsb 83 (19.1%)
Comorbidities Incidence per 1000 person-yearsc
Uveitis 6.5 (3.3–12.7)
Sjogren’s syndrome 0.8 (0.1–4.3)
Rheumatoid arthritis 3.0 (1.2–7.7)
All Bone Fracture 55.5 (44.0–69.8)
 OMDS 1–4 35.9 (19.5–66.1)
 OMDS 5 57.4 (39.2–84.2)
 OMDS 6 73.2 (46.3–115.8)
 OMDS 7–13 56.0 (35.4–88.6)
 Lower limb fracture 22.6 (15.8–32.3)
 OMDS 1–4 3.5 (0.6–19.6)
 OMDS 5 23.7 (13.3–42.5)
 OMDS 6 24.1 (11.1–52.6)
 OMDS 7–13 36.8 (21.0–64.3)
 Compression fracture 22.4 (15.7–32.0)
 OMDS 1–4 10.6 (3.6–31.1)
 OMDS 5 19.3 (10.1–36.6)
 OMDS 6 44.0 (24.6–78.9)
 OMDS 7–13 20.7 (10.0–42.8)
 Upper limb fracture 3.7 (1.6–8.6)
Herpes zoster 10.4 (6.2–17.4)
Interstitial pneumonia 1.5 (0.4–5.4)
Tuberculosis 0.0 (0.0–2.8)
Diabetes mellitusd 6.2 (3.1–12.2)
Cataractd 9.4 (5.4–16.5)
Glaucomad 2.3 (0.8–6.7)
  1. aData are expressed as mean ± standard deviation
  2. bRapid progressors were defined as those who developed OMDS 5 or above within 2 years from the onset of motor symptoms
  3. cData are expressed as point estimates and 95% confidence intervals
  4. dThese data are based on open-ended questions about comorbidities, Abbreviation: OMDS, Osame motor disability score